A citation-based method for searching scientific literature

M Kalamarides, A O Stemmer-Rachamimov, M Niwa-Kawakita, F Chareyre, E Taranchon, Z-Y Han, C Martinelli, E A Lusis, B Hegedus, D H Gutmann, M Giovannini. Oncogene 2011
Times Cited: 93







List of co-cited articles
824 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
486
39

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
377
36

Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.
Michel Kalamarides, Michiko Niwa-Kawakita, Hélène Leblois, Vincent Abramowski, Michel Perricaudet, Anne Janin, Gilles Thomas, David H Gutmann, Marco Giovannini. Genes Dev 2002
148
29

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
148
23

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz,[...]. Nat Genet 2016
171
23

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
146
22

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
22

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
330
22

Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
M H Ruttledge, J Sarrazin, S Rangaratnam, C M Phelan, E Twist, P Merel, O Delattre, G Thomas, M Nordenskjöld, V P Collins. Nat Genet 1994
443
19

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
585
19

Pathological classification and molecular genetics of meningiomas.
Christian Mawrin, Arie Perry. J Neurooncol 2010
266
18

Histological classification and molecular genetics of meningiomas.
Markus J Riemenschneider, Arie Perry, Guido Reifenberger. Lancet Neurol 2006
324
18

Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
Stéphane Goutagny, Hong Wei Yang, Jessica Zucman-Rossi, Jennifer Chan, Jonathan M Dreyfuss, Peter J Park, Peter M Black, Marco Giovannini, Rona S Carroll, Michel Kalamarides. Clin Cancer Res 2010
69
24

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
J Boström, B Meyer-Puttlitz, M Wolter, B Blaschke, R G Weber, P Lichter, K Ichimura, V P Collins, G Reifenberger. Am J Pathol 2001
179
17

"Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.
A Perry, B W Scheithauer, S L Stafford, C M Lohse, P C Wollan. Cancer 1999
434
15

Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas.
Miriam J Smith, James O'Sullivan, Sanjeev S Bhaskar, Kristen D Hadfield, Gemma Poke, John Caird, Saba Sharif, Diana Eccles, David Fitzpatrick, Daniel Rawluk,[...]. Nat Genet 2013
154
15

Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
M Peyre, A Stemmer-Rachamimov, E Clermont-Taranchon, S Quentin, N El-Taraya, C Walczak, A Volk, M Niwa-Kawakita, N Karboul, M Giovannini,[...]. Oncogene 2013
24
58

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
158
15

NF2 status of meningiomas is associated with tumour localization and histology.
J Kros, K de Greve, A van Tilborg, W Hop, H Pieterman, C Avezaat, R Lekanne Dit Deprez, E Zwarthoff. J Pathol 2001
78
16

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Marianne F James, Sangyeul Han, Carolyn Polizzano, Scott R Plotkin, Brendan D Manning, Anat O Stemmer-Rachamimov, James F Gusella, Vijaya Ramesh. Mol Cell Biol 2009
185
13

Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.
G A Rouleau, P Merel, M Lutchman, M Sanson, J Zucman, C Marineau, K Hoang-Xuan, S Demczuk, C Desmaze, B Plougastel. Nature 1993
13

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
304
13

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
188
13

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
12


A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas.
Arie Perry, Ruma Banerjee, Christine M Lohse, Bette K Kleinschmidt-DeMasters, Bernd W Scheithauer. Brain Pathol 2002
112
12

mTORC1 inhibitors suppress meningioma growth in mouse models.
Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, Christian Mawrin. Clin Cancer Res 2013
68
17

Genomic landscape of intracranial meningiomas.
Wenya Linda Bi, Malak Abedalthagafi, Peleg Horowitz, Pankaj K Agarwalla, Yu Mei, Ayal A Aizer, Ryan Brewster, Gavin P Dunn, Ossama Al-Mefty, Brian M Alexander,[...]. J Neurosurg 2016
60
20

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Ganesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, Parker H Merrill, Naema Nayyar, Corey M Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K Agarwalla, Aaron R Thorner,[...]. Neuro Oncol 2017
67
17

Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
Akdes Serin Harmancı, Mark W Youngblood, Victoria E Clark, Süleyman Coşkun, Octavian Henegariu, Daniel Duran, E Zeynep Erson-Omay, Leon D Kaulen, Tong Ihn Lee, Brian J Abraham,[...]. Nat Commun 2017
91
13

WHO grade II and III meningiomas: a study of prognostic factors.
Anne Durand, François Labrousse, Anne Jouvet, Luc Bauchet, Michel Kalamaridès, Philippe Menei, Robert Deruty, Jean Jacques Moreau, Michelle Fèvre-Montange, Jacques Guyotat. J Neurooncol 2009
202
11

A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.
J A Trofatter, M M MacCollin, J L Rutter, J R Murrell, M P Duyao, D M Parry, R Eldridge, N Kley, A G Menon, K Pulaski. Cell 1993
11

AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
Felix Sahm, Juliane Bissel, Christian Koelsche, Leonille Schweizer, David Capper, David Reuss, Katja Böhmer, Ulrike Lass, Tanja Göck, Katrin Kalis,[...]. Acta Neuropathol 2013
68
16

Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas.
Miriam J Smith, Andrew J Wallace, Chris Bennett, Martin Hasselblatt, Ewelina Elert-Dobkowska, Linton T Evans, William F Hickey, Jack van Hoff, David Bauer, Amy Lee,[...]. J Pathol 2014
77
14

Genomic landscape of high-grade meningiomas.
Wenya Linda Bi, Noah F Greenwald, Malak Abedalthagafi, Jeremiah Wala, Will J Gibson, Pankaj K Agarwalla, Peleg Horowitz, Steven E Schumacher, Ekaterina Esaulova, Yu Mei,[...]. NPJ Genom Med 2017
85
12

The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Katherine Striedinger, Scott R VandenBerg, Gilson S Baia, Michael W McDermott, David H Gutmann, Anita Lal. Neoplasia 2008
102
10

BAP1 mutations in high-grade meningioma: implications for patient care.
Ganesh M Shankar, Sandro Santagata. Neuro Oncol 2017
80
12

Advances in meningioma genetics: novel therapeutic opportunities.
Matthias Preusser, Priscilla K Brastianos, Christian Mawrin. Nat Rev Neurol 2018
78
12

Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.
Harish N Vasudevan, Steve E Braunstein, Joanna J Phillips, Melike Pekmezci, Bryan A Tomlin, Ashley Wu, Gerald F Reis, Stephen T Magill, Jie Zhang, Felix Y Feng,[...]. Cell Rep 2018
47
21

Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri.
Pepijn van den Munckhof, Imke Christiaans, Susan B Kenter, Frank Baas, Theo J M Hulsebos. Neurogenetics 2012
81
11

Establishment of a benign meningioma cell line by hTERT-mediated immortalization.
Sylvia Püttmann, Volker Senner, Stephan Braune, Beate Hillmann, Rita Exeler, Christian H Rickert, Werner Paulus. Lab Invest 2005
76
11

Medical therapies for meningiomas.
Patrick Y Wen, Eudocia Quant, Jan Drappatz, Rameen Beroukhim, Andrew D Norden. J Neurooncol 2010
101
9

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
9

Role of Merlin/NF2 inactivation in tumor biology.
A M Petrilli, C Fernández-Valle. Oncogene 2016
173
9

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
Ayal A Aizer, Malak Abedalthagafi, Wenya Linda Bi, Margaret C Horvath, Nils D Arvold, Ossama Al-Mefty, Eudocia Q Lee, Lakshmi Nayak, Mikael L Rinne, Andrew D Norden,[...]. Neuro Oncol 2016
48
18

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
377
9

Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.
R G Weber, J Boström, M Wolter, M Baudis, V P Collins, G Reifenberger, P Lichter. Proc Natl Acad Sci U S A 1997
308
8

Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas.
I Christiaans, S B Kenter, H C Brink, T A M van Os, F Baas, P van den Munckhof, A M J Kidd, T J M Hulsebos. J Med Genet 2011
89
8

Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
M Giovannini, E Robanus-Maandag, M van der Valk, M Niwa-Kawakita, V Abramowski, L Goutebroze, J M Woodruff, A Berns, G Thomas. Genes Dev 2000
256
8

Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Eriks A Lusis, Mark A Watson, Michael R Chicoine, Meghan Lyman, Peter Roerig, Guido Reifenberger, David H Gutmann, Arie Perry. Cancer Res 2005
165
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.